Nektar Therapeutics

Jurisdiction

United States

LEI

5299005I24806IOIYE03

ISIN

US6402681083

(NKTR)

Sectors

Scores

InsiderPie Expert Score: 50 / 100
Even with peer group:: 50 / 100
Fair value (Benjamin Graham formula): N/A
Financial strength (Piotroski F-Value): 3 / 9
Fundamental strength relative to industry (Mohanram G-Value): 2 / 7

Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. Read full profile

Fundamentals

Net revenue: €63.92M
Gross margin: 83.2%
EBIT: -€85.95M
EBIT margin: -134.5%
Net income: -€104.29M
Net margin: -163.2%

Statement period: July 1, 2024 - June 30, 2025 (published August 8, 2025)

Estimates

Fiscal Year	Net revenue	Net income
2026	€34.65M -45.8%	-€176.86M +69.6%
2027	€29.03M -16.2%	-€221.31M +25.1%
2028	€51.05M +75.8%	-€290.21M +31.1%

Dividends

No dividend payouts

Analyst ratings

No analyst ratings available

Insider Transactions

Name	Title	Transaction Date	Shares	Price	Value
ROBIN HOWARD W	President & CEO	September 2, 2025	-1.5K	$30.16	-$45.24K
Zalevsky Jonathan	Chief R&D Officer	September 2, 2025	-485	$30.10	-$14.60K
ROBIN HOWARD W	President & CEO	August 19, 2025	-1.6K	$26.59	-$41.83K
Wilson Mark Andrew	Chief Legal Officer	August 19, 2025	-676	$26.59	-$17.97K
Zalevsky Jonathan	Chief R&D Officer	August 19, 2025	-725	$26.59	-$19.28K